$XTNT Cashflow Statement | Understand Stock

$XTNT

$0.28 -$0.01 (2.55%) Close

$XTNT Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities:
Net income (loss)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization
Non-cash interest
Non-cash rent
Loss (gain) on sale of fixed assets
Stock-based compensation
Provision for reserve on accounts receivable
Provision for excess and obsolete inventory
Deferred income taxes
Gain on bargain purchase
Gain on divestiture
Other
Changes in operating assets and liabilities:
Trade accounts receivable
Inventories
Prepaid and other assets
Accounts payable
Accrued liabilities
Net cash provided by (used in) operating activities
Investing activities:
Purchases of property and equipment
Proceeds from sale of fixed assets
Acquisition of Surgalign SPV, Inc.
Acquisition of Surgalign Holdings, Inc.’s hardware and biologics business, net of cash acquired
Acquisition of nanOss Production Operations from RTI Surgical Inc.
Proceeds from divestiture
Net cash provided by (used in) investing activities
Financing activities:
Borrowings on line of credit
Repayments on line of credit
Payments on long-term debt
Payments on financing leases
Proceeds from issuance of common stock, net of issuance costs
Proceeds from private placement, net of issuance costs
Proceeds from issuance of long-term debt
Debt issuance costs
Payment of taxes from withholding of common stock upon vesting and settlement of restricted stock units
Costs associated with refinancing
Proceeds from exercise of stock-based compensation
Net cash (used in) provided by financing activities

Effect of exchange rate changes on cash and cash equivalents and restricted cash
Net change in cash and cash equivalents and restricted cash
Cash and cash equivalents and restricted cash at beginning of year
Cash and cash equivalents and restricted cash at end of year
Reconciliation of cash and cash equivalents and restricted cash reported in the consolidated balance sheets
Cash and cash equivalents
Restricted cash
Total cash and cash equivalents and restricted cash reported in the consolidated balance sheets

Comments